HC Wainwright Reaffirms “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. HC Wainwright also issued estimates for 60 Degrees Pharmaceuticals’ Q1 2025 earnings at ($2.81) EPS, Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.53) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, February 19th.

60 Degrees Pharmaceuticals Stock Up 4.7 %

SXTP opened at $2.01 on Tuesday. The stock has a market cap of $2.96 million, a price-to-earnings ratio of -0.20 and a beta of 4.22. The company’s 50-day moving average price is $4.41 and its two-hundred day moving average price is $5.52. 60 Degrees Pharmaceuticals has a twelve month low of $1.78 and a twelve month high of $35.99.

Insider Transactions at 60 Degrees Pharmaceuticals

In other news, CEO Geoffrey S. Dow purchased 7,164 shares of the stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $6.35 per share, with a total value of $45,491.40. Following the completion of the acquisition, the chief executive officer now owns 18,916 shares in the company, valued at $120,116.60. This represents a 60.96 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders purchased 12,073 shares of company stock valued at $76,966 over the last three months. Company insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.